Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34035488)

  • 1. Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes.
    Wu YL; Xue YR; Guo ZT; Chen ZD; Ge XY; Zhong DF; Diao XX
    Acta Pharmacol Sin; 2022 Mar; 43(3):747-756. PubMed ID: 34035488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer.
    Liu XY; Guo ZT; Chen ZD; Zhang YF; Zhou JL; Jiang Y; Zhao QY; Diao XX; Zhong DF
    Acta Pharmacol Sin; 2020 Oct; 41(10):1366-1376. PubMed ID: 32235864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers.
    Zhu YT; Zhang YF; Jiang JF; Yang Y; Guo LX; Bao JJ; Zhong DF
    Invest New Drugs; 2021 Aug; 39(4):1011-1018. PubMed ID: 33506323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes.
    Hendriks DFG; Vorrink SU; Smutny T; Sim SC; Nordling Å; Ullah S; Kumondai M; Jones BC; Johansson I; Andersson TB; Lauschke VM; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2020 Oct; 108(4):844-855. PubMed ID: 32320483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes.
    Prueksaritanont T; Richards KM; Qiu Y; Strong-Basalyga K; Miller A; Li C; Eisenhandler R; Carlini EJ
    Pharm Res; 2005 Jan; 22(1):71-8. PubMed ID: 15771232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Suppression of CYP3A4 mRNA and Enzyme Activity by Epidermal Growth Factor in Plated Human Hepatocytes.
    Zhang JG; Wang D; Ho T; Clark RJ; Stresser DM
    Drug Metab Lett; 2017; 11(2):119-127. PubMed ID: 29189189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative.
    Luo G; Lin J; Fiske WD; Dai R; Yang TJ; Kim S; Sinz M; LeCluyse E; Solon E; Brennan JM; Benedek IH; Jolley S; Gilbert D; Wang L; Lee FW; Gan LS
    Drug Metab Dispos; 2003 Sep; 31(9):1170-5. PubMed ID: 12920173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital.
    Hariparsad N; Nallani SC; Sane RS; Buckley DJ; Buckley AR; Desai PB
    J Clin Pharmacol; 2004 Nov; 44(11):1273-81. PubMed ID: 15496645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction.
    Kapetas AJ; Sorich MJ; Rodrigues AD; Rowland A
    AAPS J; 2019 Jun; 21(5):78. PubMed ID: 31218462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
    Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
    Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Normalization Methods To Predict CYP3A4 Induction in Six Fully Characterized Cryopreserved Human Hepatocyte Preparations and HepaRG Cells.
    Vermet H; Raoust N; Ngo R; Esserméant L; Klieber S; Fabre G; Boulenc X
    Drug Metab Dispos; 2016 Jan; 44(1):50-60. PubMed ID: 26467767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate.
    Nallani SC; Glauser TA; Hariparsad N; Setchell K; Buckley DJ; Buckley AR; Desai PB
    Epilepsia; 2003 Dec; 44(12):1521-8. PubMed ID: 14636322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.
    Prueksaritanont T; Kuo Y; Tang C; Li C; Qiu Y; Lu B; Strong-Basalyga K; Richards K; Carr B; Lin JH
    Drug Metab Dispos; 2006 Sep; 34(9):1546-55. PubMed ID: 16782766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
    Baneyx G; Parrott N; Meille C; Iliadis A; Lavé T
    Eur J Pharm Sci; 2014 Jun; 56():1-15. PubMed ID: 24530864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based Relative Induction Score Approach.
    Zuo R; Li F; Parikh S; Cao L; Cooper KL; Hong Y; Liu J; Faris RA; Li D; Wang H
    Drug Metab Dispos; 2017 Feb; 45(2):198-207. PubMed ID: 28062541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes.
    Madan A; Graham RA; Carroll KM; Mudra DR; Burton LA; Krueger LA; Downey AD; Czerwinski M; Forster J; Ribadeneira MD; Gan LS; LeCluyse EL; Zech K; Robertson P; Koch P; Antonian L; Wagner G; Yu L; Parkinson A
    Drug Metab Dispos; 2003 Apr; 31(4):421-31. PubMed ID: 12642468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers.
    Heng J; Tang Q; Chen X; Bao J; Deng J; Chen Y; Zhao J; Zhu S; Liu X; Yang F; Jiang Y; Yang N; Li K
    Eur J Pharm Sci; 2021 Jul; 162():105815. PubMed ID: 33771716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers.
    Li AP
    Drug Metab Dispos; 2009 Aug; 37(8):1598-603. PubMed ID: 19451401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole.
    Liu X; Zhang Y; Chen Q; Zhan Y; Wang Q; Hu C; Yu C; Guo Z; Chen X; Zhong D
    J Clin Pharmacol; 2018 Mar; 58(3):347-356. PubMed ID: 28967981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich culture.
    Badolo L; Jensen B; Säll C; Norinder U; Kallunki P; Montanari D
    Xenobiotica; 2015 Feb; 45(2):177-87. PubMed ID: 25183402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.